Journal: Journal of leukocyte biology

Article Title: Involvement of fibrinolytic regulators in adhesion of monocytes to vascular endothelial cells induced by glycated LDL and to aorta from diabetic mice.

doi: 10.1189/jlb.0513262

Figure Lengend Snippet: Figure 2. Effects of glyLDL on the expression of uPA, uPAR, LRP, P-selectin, ICAM-1, and MCP-1 and the impact of uPA on PAI-1 in EC. (A and B) HUVEC were treated with vehicle [control (ctr)], 50– 150 g/ml glyLDL (gLDL) for 1–12 h for uPA. (C) HUVEC were treated with 1 g/ml uPA or vehi- cle for 30 min, and the incubation was continued by adding vehicle of 100 g/ml glyLDL for 24 h. (D and E) HUVEC were treated with vehicle or 100 g/ml glyLDL for 1–24 h for ICAM-1, P-selectin (P-sel), and MCP-1. Abundances of uPA, uPAR, LRP, ICAM-1, P-selectin, MCP-1, PAI-1, and -actin in EC were analyzed using Western blotting and assessed semiquantitatively using ChemiDoc software. Values were expressed in folds of control after normalization with -actin (meansd; n3 independent experiments). sal., Saline. *P 0.05; **P 0.01 versus vehicle control; P 0.01 versus glyLDL.

Article Snippet: Targeted proteins in total cellular proteins of EC were analyzed using Western blotting analysis, as described previously [5]. mAb or polyclonal antibodies against human PAI-1, uPA, uPAR, HSF1, p22-phox, ICAM-1, P-selectin, monocyte adhesion protein (MCP)-1, LRP, or -actin were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA) or Abcam (Cambridge, UK).

Techniques: Expressing, Control, Incubation, Western Blot, Software, Saline

Journal: Cells

Article Title: Lactate-Induced HBEGF Shedding and EGFR Activation: Paving the Way to a New Anticancer Therapeutic Opportunity

doi: 10.3390/cells13181533

Figure Lengend Snippet: List of the antibodies used for protein detection.

Article Snippet: IB, primary , uPA , rabbit , A2181 , AB Clonal (a) , 1:2000 , 2 h.

Techniques:

Journal: Oncology letters

Article Title: Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.

doi: 10.3892/ol.2016.4498

Figure Lengend Snippet: Figure 1. mRNA expression of uPA, uPAR and PAI‑1 in four gastric cancer cell lines. (A) uPA, (B) PAI‑1 and (C) uPAR. The upper lane in each image represents the uPA, uPAR and PAI‑1 expression, respectively, while the lower lane in each image represents the internal reference gene expression. The internal reference gene for uPA and PAI‑1 was glyceraldehyde 3‑phosphate dehydrogenase, and for uPAR was β‑actin. Lane 1, AGS cell line; lane 2, SGC7901 cell line; lane 3, MKN45 cell line; and lane 4, MKN28 cell line. M, DNA marker; uPA, urokinase‑type plasminogen activator; uPAR, uPA receptor; PAI‑1, plasminogen activator inhibitor‑1.

Article Snippet: The membrane was blocked with 5% skimmed milk for 3 h, and was subsequently incubated for 3 h with monoclonal mouse anti-human uPA antibody (dilution, 1:500; catalog no., TA805243; OriGene Technologies, Inc., Rockville, MD, USA), monoclonal mouse anti-human uPAR antibody (dilution, 1:500; catalog no., sc-376494; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and monoclonal mouse anti-human PAI-1 antibody (dilution, 1:500; catalog no., sc-5297; Santa Cruz Biotechnology, Inc.), respectively.

Techniques: Expressing, Gene Expression, Marker

Journal: Oncology letters

Article Title: Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.

doi: 10.3892/ol.2016.4498

Figure Lengend Snippet: Figure 2. uPA, uPAR and PAI‑1 protein expression in four gastric cancer cell lines: (A) uPA (60 kDa), the upper lane demonstrates the expression of combined uPA, and the lower lane is the expression of single uPA (52 kDa); (B) uPAR (60 kDa); (C) PAI‑1, the upper lane is the expression of combined PAI‑1 (60 kDa), and the lower lane is the expression of single PAI‑1 (47 kDa). (D) Protein expression levels of combined uPA, single uPA, uPAR, combined PAI‑1 and single PAI‑1 the four gastric cancer cell lines. Lane 1, AGS cell line; lane 2, SGC7901 cell line; lane 3, MKN45 cell line; lane 4, MKN28 cell line; M, DNA marker; uPA, urokinase‑type plasminogen activator; uPAR, uPA receptor; PAI‑1, plasminogen activator inhibitor‑1.

Article Snippet: The membrane was blocked with 5% skimmed milk for 3 h, and was subsequently incubated for 3 h with monoclonal mouse anti-human uPA antibody (dilution, 1:500; catalog no., TA805243; OriGene Technologies, Inc., Rockville, MD, USA), monoclonal mouse anti-human uPAR antibody (dilution, 1:500; catalog no., sc-376494; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and monoclonal mouse anti-human PAI-1 antibody (dilution, 1:500; catalog no., sc-5297; Santa Cruz Biotechnology, Inc.), respectively.

Techniques: Expressing, Marker

Journal: Oncology letters

Article Title: Effect of urokinase-type plasminogen activator system in gastric cancer with peritoneal metastasis.

doi: 10.3892/ol.2016.4498

Figure Lengend Snippet: Figure 6. Inhibition percentage of the uPA system on biological behaviors in the MKN45 cells. (A) Inhibition percentage of the uPA system on adhesion. (B) Inhibition percentage of the uPA system on migration. (C) Inhibition percentage of the uPA system on invasion. uPA, urokinase‑type plasminogen activator; uPAR, uPA receptor; PAI‑1, plasminogen activator inhibitor‑1.

Article Snippet: The membrane was blocked with 5% skimmed milk for 3 h, and was subsequently incubated for 3 h with monoclonal mouse anti-human uPA antibody (dilution, 1:500; catalog no., TA805243; OriGene Technologies, Inc., Rockville, MD, USA), monoclonal mouse anti-human uPAR antibody (dilution, 1:500; catalog no., sc-376494; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) and monoclonal mouse anti-human PAI-1 antibody (dilution, 1:500; catalog no., sc-5297; Santa Cruz Biotechnology, Inc.), respectively.

Techniques: Inhibition, Migration